Prothena | PRTA - Gross Profit On Sales

Stock Price
8.91
Daily Change
0.56 6.71%
Monthly
-2.41%
Yearly
-36.58%
Q1 Forecast
8.55

Prothena reported $2.42M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 256.99M 13.15M Sep/2025
Agios Pharmaceuticals USD 11.2M 448K Sep/2025
ALKERMES USD 265.83M 8.06M Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Exelixis USD 579.18M 30.39M Sep/2025
Incyte USD 1.27B 130.22M Sep/2025
Ionis Pharmaceuticals USD 155M 293M Sep/2025
MacroGenics USD 61.25M 88.71M Sep/2025
Neurocrine Biosciences USD 780.9M 104.7M Sep/2025
Prothena USD 2.42M 38.52M Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025